Back to search

Democritus University of Thrace (DUTH)

Nanotherapeutic approaches to epithelial cancers

Abstract

dc:description

Cancer is a leading cause of death worldwide and its global burden continues to rise, largely because of the growth and aging of the world population. Resistance to cell death and reprogramming of metabolic pathways are two hallmarks of human cancer cells as well as major causes of chemotherapy inefficacy. After conventional chemotherapy, a high percentage of patients is inevitably prone to profound toxicity in normal cells/tissue and drug resistance. The past few years advanced nanomedicines have been shown to be more effective than conventional chemotherapy. Furthermore, effectiveness of cancer battling can be improved substantially if chemotherapeutics cytotoxicity is combined with anticancer immunosurveillance. In this thesis, the development of a targeted drug nanodelivery platform, against tumor microenvironment, targeting endosialin/tumor endothelial marker 1 (TEM1)/CD248 is described. Biocompatible, and biodegradable polylactide-co-glycolide acid (PLGA) nanoparticles (NPs) loaded with shikonin (SHK) and coated with polyethyleneglycol (PEG) and anti-TEM1 targeting device (whole antibody, antibody’s Fc part or antibody’s scFv part) were designed and formulated. Based on particle size analysis and electron microscopy, the engineered NPs showed a smooth spherical shape with size ranging between 100-125 nm and a zeta potential value of -30 to -40 mV. Drug entrapment and bioconjugation efficiency reached ~92% and ~90% respectively. SHK showed sustained-release profile in PBS and serum, which fitted various kinetics models, and was best fitted with Wagner log-probability model. The SHK mechanism of cellular toxicity, both as free drug and as nanoformulation, was studied in vitro and in vivo. SHK was found to cause apoptosis and necroptosis to all the cell lines studied. SHK was profoundly toxic in ovarian epithelial cancer cells (OVCAR-5 and ID8 cells) as well as in normal ovarian IOSE-398 cells, endothelial MS1 cells, epithelial TC1 cells and lymphocytes. SHK induced mitochondrial depolarization, formation of reactive oxygen species (ROS), autophagosomes, nuclei heterochromatin foci and DNA fragmentation in vitro. Fluorescence microscopy and flow cytometry analysis showed active interaction of Ab-armed NPs with TEM1-positive MS1 cells, but not with TEM1-negative MS1 cells, while exposure of lymphocytes to PEGylated NPs for 2 hours was not toxic. To address regulatory, clearance and toxicity issues, biodistribution studies were performed. NPs were not retained in liver/spleen and were excreted via urine track. Targeting efficacy in vivo was studied using the MS1 xenograft mouse model. SHK-loaded, 78Fc-armed NPs showed higher accumulation and killing efficiency at the TEM1-positive tumor site compared to free drug/unarmed NPs. TC1 murine lung carcinoma subcutaneous and intravenous/metastatic models were selected to evaluate efficiency in aggressive tumor models. In both models, 78Fc-armed NPs increased dramatically SHK cytotoxicity compared to unarmed NPs/free drug. TC1 subcutaneous model was studied in C57/BL6 mice. Accelerated blood clearance phenomenon was not observed and interestingly, the 78Fc-armed NPs had better therapeutic effect to C57/BL6 mice compared to naïve mice, suggesting potent synergism with the immune system. ELISPOT assay was performed to investigate specific immune response to E6/E7 antigens. Furthermore, mice that received the NPs treatment and became tumor free, were rechallenged with tumor cells to investigate specific immune response. The rechallenged mice remained tumor free 14 days after rechallenging. This observation implies that our targeted nanotherapeutic approach not only had a high efficacy but also stimulated a sustained immune response. Based upon all all our data, I SHK-loaded, anti-TEM1 Fc-armed PLGA NPs may be supposed as novel targeted therapy against TEM1 expressing carcinomas.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Matthaiou, Efthymia-Iliana
  • Ματθαίου, Ευθυμία-Ηλιάνα

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40575

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Matthaiou, Efthymia-Iliana; Ματθαίου, Ευθυμία-Ηλιάνα. Nanotherapeutic approaches to epithelial cancers. Democritus University of Thrace (DUTH), 2017. http://hdl.handle.net/10442/hedi/40575